XML 69 R57.htm IDEA: XBRL DOCUMENT
v3.22.2

License and Collaboration Agreements - Additional Information (Details) - USD ($) $ in Thousands |  | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | --- | ---
Mar. 29, 2021 | Aug. 31, 2020 | Jun. 30, 2022 | Dec. 31, 2021 | Jun. 30, 2021 | Jun. 30, 2022 | Dec. 31, 2021 | Jun. 30, 2021 | Dec. 31, 2021 | Feb. 28, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenue |  |  | $ 73,746 |  |  | $ 54,024 | $ 75,440 |  |  | $ 54,486 |  |  |
Deferred revenue, current portion |  |  | 7,190 |  |  |  | 7,190 |  |  |  |  |  |
Receivable from licensing and collaboration agreements |  |  | 22,821 | $ 19,749 | [1] |  | 22,821 | $ 19,749 | [1] |  | $ 19,749 | [1] |
Research and development |  |  | 108,400 |  |  | 101,960 | 216,049 |  |  | 224,519 |  |  |
ASC 808 |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Receivable from licensing and collaboration agreements |  |  | 15,500 | 5,900 |  |  | 15,500 | 5,900 |  |  | 5,900 |  |
Research and development |  |  |  |  |  | 19,500 | 2,900 |  |  | 19,500 |  |  |
License agreements share of co-commercialization loss as reduction to selling, general and administrative expenses |  |  | 200 |  |  | 4,100 | 1,300 |  |  | 4,100 |  |  |
License and Collaboration Agreement | BMS |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment yet to be received |  |  | 90,000 |  |  |  | 90,000 |  |  |  |  |  |
Upfront, regulatory and launch milestone payments yet to be received |  |  | 815,000 |  |  |  | 815,000 |  |  |  |  |  |
License and Collaboration Agreement | Helsinn Therapeutics |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage share of global development costs | 60.00% |  |  |  |  |  |  |  |  |  |  |  |
License and Collaboration Agreement | Helsinn Therapeutics | License and Services Revenue | ASC 808 |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Receivable from licensing and collaboration agreements |  |  | 600 | 0 |  |  | 600 | 0 |  |  | 0 |  |
License and Collaboration Agreement | Helsinn Therapeutics | License and Services Revenue | ASC 606 |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenue |  |  |  |  |  | 44,400 |  |  |  | 44,400 |  |  |
Receivable from licensing and collaboration agreements |  |  | 200 | 10,000 |  |  | 200 | 10,000 |  |  | 10,000 |  |
License and Collaboration Agreement | QED Therapeutics, Inc |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront, regulatory and launch milestone payments yet to be received | $ 100,000 |  |  |  |  |  |  |  |  |  |  |  |
License agreement percentage share of profits and losses | 50.00% |  |  |  |  |  |  |  |  |  |  |  |
Percentage share of global development costs | 40.00% |  |  |  |  |  |  |  |  |  |  |  |
Regulatory and sales-based milestone payments yet to be received |  |  |  |  |  |  |  |  |  |  |  |  | $ 66,000
License and Collaboration Agreement | QED Therapeutics, Inc | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments | $ 2,450,000 |  |  |  |  |  |  |  |  |  |  |  |
License and Collaboration Agreement | QED Therapeutics, Inc | Helsinn Therapeutics |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Initial transaction price for the license and collaboration agreement | 46,000 |  |  |  |  |  |  |  |  |  | 56,000 |  |
Nonrefundable upfront license fee | 20,000 |  |  |  |  |  |  |  |  |  |  |  |
Sale of certain existing inventory | 1,000 |  |  |  |  |  |  |  |  |  |  |  |
Launch milestone payment | $ 25,000 |  |  |  |  |  |  |  |  |  |  |  |
Increase in initial transaction price for license and collaboration agreement |  |  |  | $ 10,000 |  |  |  |  |  |  |  |  |
Allocation of transaction price to licenses |  |  |  |  |  |  |  |  |  |  | 54,400 |  |
Allocation of transaction price to transfer of certain existing inventory |  |  |  |  |  |  |  | $ 1,600 |  |  | $ 1,600 |  |
Receivable from licensing and collaboration agreements |  |  | 12,500 |  |  |  | 12,500 |  |  |  |  |  |
Research and development |  |  | 9,500 |  |  |  | $ 12,800 |  |  |  |  |  |
Reimbursement percentage of research and development costs incurred |  |  |  |  |  |  | 100.00% |  |  |  |  |  |
License agreements share of co-commercialization loss as reduction to selling, general and administrative expenses |  |  | 400 |  |  |  | $ 500 |  |  |  |  |  |
Reimbursement percentage of commercial activity costs incurred |  |  |  |  |  |  | 100.00% |  |  |  |  |  |
License and Collaboration Agreement | Navire Pharma, Inc | BMS |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments |  |  | 0 |  |  |  | $ 0 |  |  |  |  |  |
Initial transaction price for the license and collaboration agreement |  |  |  |  |  |  | 90,000 |  |  |  |  |  |
Allocation Of transaction price for research and development |  |  |  |  |  |  | 19,800 |  |  |  |  |  |
Allocation of transaction price to licenses |  |  |  |  |  |  | 70,200 |  |  |  |  |  |
Total revenue |  |  | 73,400 |  |  |  | 73,400 |  |  |  |  |  |
Deferred Revenue |  |  | 16,600 |  |  |  | 16,600 |  |  |  |  |  |
Deferred revenue, current portion |  |  | 7,200 |  |  |  | 7,200 |  |  |  |  |  |
Deferred Revenue Noncurrent |  |  | 9,400 |  |  |  | 9,400 |  |  |  |  |  |
License and Collaboration Agreement | Navire Pharma, Inc | Research and Development Services Performance Obligation | BMS |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenue |  |  | 3,200 |  |  |  | 3,200 |  |  |  |  |  |
License and Collaboration Agreement | Receivable from Licensing and Collaboration Agreements [Member] | QED Therapeutics, Inc | Helsinn Therapeutics |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Receivable from licensing and collaboration agreements |  |  | 4,000 |  |  |  | 4,000 |  |  |  |  |  |
License and Collaboration Agreement | Other Noncurrent Assets [Member] | QED Therapeutics, Inc | Helsinn Therapeutics |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Receivable from licensing and collaboration agreements |  |  | 8,500 |  |  |  | 8,500 |  |  |  |  |  |
License Agreement | LianBio |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Nonrefundable upfront payment receivable |  |  |  |  |  |  | 8,000 |  |  |  |  |  |
License Agreement | LianBio | License and Services Revenue |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenue |  |  | $ 0 |  |  | $ 8,500 | $ 0 |  |  | $ 8,500 |  |  |
License Agreement | LianBio | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Future potential development and sales milestone payments yet to receive |  | $ 382,100 |  |  |  |  |  |  |  |  |  |  |
[1] | The condensed consolidated balance sheet as of December 31, 2021 is derived from the audited consolidated financial statements as of that date.

X
- Definition Allocation Of Transaction Price for Research and Development. + References No definition available. + Details
Name: | bbio_AllocationOfTransactionPriceForResearchAndDevelopment
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Allocation of transaction price to licenses. + References No definition available. + Details
Name: | bbio_AllocationOfTransactionPriceToLicenses
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Allocation of transaction price to transfer of existing inventory. + References No definition available. + Details
Name: | bbio_AllocationOfTransactionPriceToTransferOfExistingInventory
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Future potential development and sales milestone payments yet to be received. + References No definition available. + Details
Name: | bbio_FuturePotentialDevelopmentAndSalesMilestonePaymentsYetToBeReceived
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Increase in initial transaction price for license and collaboration agreement. + References No definition available. + Details
Name: | bbio_IncreaseInInitialTransactionPriceForLicenseAndCollaborationAgreement
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Initial transaction price for license and collaboration agreement. + References No definition available. + Details
Name: | bbio_InitialTransactionPriceForLicenseAndCollaborationAgreement
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Launch milestone payment. + References No definition available. + Details
Name: | bbio_LaunchMilestonePayment
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License agreement percentage share of profits and losses. + References No definition available. + Details
Name: | bbio_LicenseAgreementPercentageShareOfProfitsAndLosses
Namespace Prefix: | bbio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition License agreements share of co-commercialization loss as reduction to selling, general and administrative expenses. + References No definition available. + Details
Name: | bbio_LicenseAgreementsShareOfCoCommercializationLossAsReductionToSellingGeneralAndAdministrativeExpenses
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Nonrefundable upfront license fees. + References No definition available. + Details
Name: | bbio_NonrefundableUpfrontLicenseFees
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Nonrefundable upfront payment receivable. + References No definition available. + Details
Name: | bbio_NonrefundableUpfrontPaymentReceivable
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage share of global development costs. + References No definition available. + Details
Name: | bbio_PercentageShareOfGlobalDevelopmentCosts
Namespace Prefix: | bbio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential milestone payments. + References No definition available. + Details
Name: | bbio_PotentialMilestonePayments
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Regulatory and sales-based milestone payments yet to be received. + References No definition available. + Details
Name: | bbio_RegulatoryAndSalesBasedMilestonePaymentsYetToBeReceived
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Reimbursement percentage of commercial activity costs incurred. + References No definition available. + Details
Name: | bbio_ReimbursementPercentageOfCommercialActivityCostsIncurred
Namespace Prefix: | bbio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Reimbursement percentage of research and development costs incurred. + References No definition available. + Details
Name: | bbio_ReimbursementPercentageOfResearchAndDevelopmentCostsIncurred
Namespace Prefix: | bbio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Sale of existing inventory. + References No definition available. + Details
Name: | bbio_SaleOfExistingInventory
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront payment yet to be received. + References No definition available. + Details
Name: | bbio_UpfrontPaymentYetToBeReceived
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Upfront, regulatory and launch milestone payments yet to be received. + References No definition available. + Details
Name: | bbio_UpfrontRegulatoryAndLaunchMilestonePaymentsYetToBeReceived
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_DeferredRevenueCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_DeferredRevenueNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount to be collected within one year of the balance sheet date (or one operating cycle, if longer) from customers in accordance with the contractual provisions of long-term contracts or programs including amounts billed and unbilled as of the balance sheet date. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(c)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_ReceivablesLongTermContractsOrPrograms
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201818Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bbio_LicenseAndCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bbio_BristolMyersSquibbCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bbio_HelsinnTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=bbio_QEDTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=bbio_NavirePharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=bbio_ReceivableFromLicensingAndCollaborationAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bbio_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bbio_LianBioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |